Weiwei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Weiwei Wang has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Li Wang
Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
4 shared publicationsJiahao Bu
Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications- Jianwei Wei
Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications - Liwei Ma
Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications Qimeng Wang
Department of Pathology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
2 shared publicationsXianzhi Liu
Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 164
Liquid biopsy: current applications and future directions
This review starts with the historical background and biological features to classify mainly the liquid biopsy biomarkers, such as circulating tumor DNA, circulating tumor cells, extracellular vesicles, non-coding RNAs, tumor-educated platelets and tumor-associated antigens, and also summarizes the present classification approaches and advanced detection techniques for each biomarker type. On this basis, the potential clinical uses of liquid biopsy in oncology are discussed in detail, including the early cancer detection, the prediction of the responses to chemotherapy, radiotherapy and immunotherapy, the evaluation of the treatment effects, the monitoring of the residual diseases and the investigation into the tumor heterogeneity and the resistance mechanisms. Moreover, the discussion is extended to other non-oncological fields, involving the reproduction medicine, the transplantation medicine, the neurological disorders, the infectious diseases and various chronic diseases such as the metabolic dysfunction-related liver disease and fibrosis, pulmonary fibrosis, lupus nephritis and renal fibrosis as well as rheumatoid arthritis. Finally, based on the comprehensive summary given above, this review summarizes the current status of the research on liquid biopsy, points out the main obstacles which hinder its wide application in clinic, for example, the absence of standard procedures and the necessity of large-scale prospective validation, and suggests possible future trends like the integration of multi-omics, the use of artificial intelligence in the analysis and the approach towards routine clinical practice.
- 7 September 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 164
Open AccessLiquid biopsy: current applications and future directions
This review starts with the historical background and biological features to classify mainly the liquid biopsy biomarkers, such as circulating tumor DNA, circulating tumor cells, extracellular vesicles, non-coding RNAs, tumor-educated platelets and tumor-associated antigens, and also summarizes the present classification approaches and advanced detection techniques for each biomarker type. On this basis, the potential clinical uses of liquid biopsy in oncology are discussed in detail, including the early cancer detection, the prediction of the responses to chemotherapy, radiotherapy and immunotherapy, the evaluation of the treatment effects, the monitoring of the residual diseases and the investigation into the tumor heterogeneity and the resistance mechanisms. Moreover, the discussion is extended to other non-oncological fields, involving the reproduction medicine, the transplantation medicine, the neurological disorders, the infectious diseases and various chronic diseases such as the metabolic dysfunction-related liver disease and fibrosis, pulmonary fibrosis, lupus nephritis and renal fibrosis as well as rheumatoid arthritis. Finally, based on the comprehensive summary given above, this review summarizes the current status of the research on liquid biopsy, points out the main obstacles which hinder its wide application in clinic, for example, the absence of standard procedures and the necessity of large-scale prospective validation, and suggests possible future trends like the integration of multi-omics, the use of artificial intelligence in the analysis and the approach towards routine clinical practice.
- Open Access
- 18 January 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (1) , e70168
ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy
Background: Resistance to temozolomide (TMZ) remains is an important cause of treatment failure in patients with glioblastoma multiforme (GBM). ADAR1, as a member of the ADAR family, plays an important role in cancer progression and chemotherapy resistance. However, the mechanism by which ADAR1 regulates GBM progression and TMZ resistance is still unclear.Methods: We first constructed stable transfected strains in which ADAR1 was knocked down and overexpressed to investigate the effect of ADAR1 on the first‐line glioma chemotherapy drug TMZ. Subsequently, we validated that ADAR1 induces autophagy activation and used autophagy inhibitors to suppress autophagy, demonstrating that ADAR1 enhances TMZ resistance through autophagy. We further knocked down p62 (SQSTM1) based on the overexpression of ADAR1, and the results showed that ADAR1 regulates selective autophagy through the p62 regulation. Finally, we demonstrated through mutations at both edited and nonedited sites that ADAR1 regulates selective autophagy in an edited dependent way.Results: Further analysis showed that in the presence of TMZ, elevated ADAR1 promoted TMZ induced autophagy activation. Further research revealed that ADAR1 enhances TMZ resistance through p62‐mediated selective autophagy. Further, ADAR1 regulates selective autophagy in an edited dependent way. Our results indicate a relationship between ADAR1 levels and the response of glioma patients to TMZ treatment.Conclusions: We found that the expression of ADAR1 is upregulated in GBM and is associated with tumor grade and TMZ resistance. Elevated expression of ADAR1 predicts poor prognosis in GBM patients and promotes tumor growth in vivo or in vitro.
- 18 January 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (1) , e70168
Open AccessADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy
Background: Resistance to temozolomide (TMZ) remains is an important cause of treatment failure in patients with glioblastoma multiforme (GBM). ADAR1, as a member of the ADAR family, plays an important role in cancer progression and chemotherapy resistance. However, the mechanism by which ADAR1 regulates GBM progression and TMZ resistance is still unclear.Methods: We first constructed stable transfected strains in which ADAR1 was knocked down and overexpressed to investigate the effect of ADAR1 on the first‐line glioma chemotherapy drug TMZ. Subsequently, we validated that ADAR1 induces autophagy activation and used autophagy inhibitors to suppress autophagy, demonstrating that ADAR1 enhances TMZ resistance through autophagy. We further knocked down p62 (SQSTM1) based on the overexpression of ADAR1, and the results showed that ADAR1 regulates selective autophagy through the p62 regulation. Finally, we demonstrated through mutations at both edited and nonedited sites that ADAR1 regulates selective autophagy in an edited dependent way.Results: Further analysis showed that in the presence of TMZ, elevated ADAR1 promoted TMZ induced autophagy activation. Further research revealed that ADAR1 enhances TMZ resistance through p62‐mediated selective autophagy. Further, ADAR1 regulates selective autophagy in an edited dependent way. Our results indicate a relationship between ADAR1 levels and the response of glioma patients to TMZ treatment.Conclusions: We found that the expression of ADAR1 is upregulated in GBM and is associated with tumor grade and TMZ resistance. Elevated expression of ADAR1 predicts poor prognosis in GBM patients and promotes tumor growth in vivo or in vitro.
- Open Access
- 11 April 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (4) , e14709
Nuclear autoantigenic sperm protein facilitates glioblastoma progression and radioresistance by regulating the ANXA2/STAT3 axis
Aims: Although radiotherapy is a core treatment modality for various human cancers, including glioblastoma multiforme (GBM), its clinical effects are often limited by radioresistance. The specific molecular mechanisms underlying radioresistance are largely unknown, and the reduction of radioresistance is an unresolved challenge in GBM research.Methods: We analyzed and verified the expression of nuclear autoantigenic sperm protein (NASP) in gliomas and its relationship with patient prognosis. We also explored the function of NASP in GBM cell lines. We performed further mechanistic experiments to investigate the mechanisms by which NASP facilitates GBM progression and radioresistance. An intracranial mouse model was used to verify the effectiveness of combination therapy.Results: NASP was highly expressed in gliomas, and its expression was negatively correlated with the prognosis of glioma. Functionally, NASP facilitated GBM cell proliferation, migration, invasion, and radioresistance. Mechanistically, NASP interacted directly with annexin A2 (ANXA2) and promoted its nuclear localization, which may have been mediated by phospho‐annexin A2 (Tyr23). The NASP/ANXA2 axis was involved in DNA damage repair after radiotherapy, which explains the radioresistance of GBM cells that highly express NASP. NASP overexpression significantly activated the signal transducer and activator of transcription 3 (STAT3) signaling pathway. The combination of WP1066 (a STAT3 pathway inhibitor) and radiotherapy significantly inhibited GBM growth in vitro and in vivo.Conclusion: Our findings indicate that NASP may serve as a potential biomarker of GBM radioresistance and has important implications for improving clinical radiotherapy.
- 11 April 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (4) , e14709
Open AccessNuclear autoantigenic sperm protein facilitates glioblastoma progression and radioresistance by regulating the ANXA2/STAT3 axis
Aims: Although radiotherapy is a core treatment modality for various human cancers, including glioblastoma multiforme (GBM), its clinical effects are often limited by radioresistance. The specific molecular mechanisms underlying radioresistance are largely unknown, and the reduction of radioresistance is an unresolved challenge in GBM research.Methods: We analyzed and verified the expression of nuclear autoantigenic sperm protein (NASP) in gliomas and its relationship with patient prognosis. We also explored the function of NASP in GBM cell lines. We performed further mechanistic experiments to investigate the mechanisms by which NASP facilitates GBM progression and radioresistance. An intracranial mouse model was used to verify the effectiveness of combination therapy.Results: NASP was highly expressed in gliomas, and its expression was negatively correlated with the prognosis of glioma. Functionally, NASP facilitated GBM cell proliferation, migration, invasion, and radioresistance. Mechanistically, NASP interacted directly with annexin A2 (ANXA2) and promoted its nuclear localization, which may have been mediated by phospho‐annexin A2 (Tyr23). The NASP/ANXA2 axis was involved in DNA damage repair after radiotherapy, which explains the radioresistance of GBM cells that highly express NASP. NASP overexpression significantly activated the signal transducer and activator of transcription 3 (STAT3) signaling pathway. The combination of WP1066 (a STAT3 pathway inhibitor) and radiotherapy significantly inhibited GBM growth in vitro and in vivo.Conclusion: Our findings indicate that NASP may serve as a potential biomarker of GBM radioresistance and has important implications for improving clinical radiotherapy.
- Open Access
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer
Radiotherapy induces a type I interferon–mediated (T1IFN-mediated) antitumoral immune response that we hypothesized could be potentiated by a first-in-class ataxia telangiectasia mutated (ATM) inhibitor, leading to enhanced innate immune signaling, T1IFN expression, and sensitization to immunotherapy in pancreatic cancer. We evaluated the effects of AZD1390 or a structurally related compound, AZD0156, on innate immune signaling and found that both inhibitors enhanced radiation-induced T1IFN expression via the POLIII/RIG-I/MAVS pathway. In immunocompetent syngeneic mouse models of pancreatic cancer, ATM inhibitor enhanced radiation-induced antitumoral immune responses and sensitized tumors to anti–PD-L1, producing immunogenic memory and durable tumor control. Therapeutic responses were associated with increased intratumoral CD8 + T cell frequency and effector function. Tumor control was dependent on CD8 + T cells, as therapeutic efficacy was blunted in CD8 + T cell–depleted mice. Adaptive immune responses to combination therapy provided systemic control of contralateral tumors outside of the radiation field. Taken together, we show that a clinical candidate ATM inhibitor enhances radiation-induced T1IFN, leading to both innate and subsequent adaptive antitumoral immune responses and sensitization of otherwise resistant pancreatic cancer to immunotherapy.
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Open AccessPotentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer
Radiotherapy induces a type I interferon–mediated (T1IFN-mediated) antitumoral immune response that we hypothesized could be potentiated by a first-in-class ataxia telangiectasia mutated (ATM) inhibitor, leading to enhanced innate immune signaling, T1IFN expression, and sensitization to immunotherapy in pancreatic cancer. We evaluated the effects of AZD1390 or a structurally related compound, AZD0156, on innate immune signaling and found that both inhibitors enhanced radiation-induced T1IFN expression via the POLIII/RIG-I/MAVS pathway. In immunocompetent syngeneic mouse models of pancreatic cancer, ATM inhibitor enhanced radiation-induced antitumoral immune responses and sensitized tumors to anti–PD-L1, producing immunogenic memory and durable tumor control. Therapeutic responses were associated with increased intratumoral CD8 + T cell frequency and effector function. Tumor control was dependent on CD8 + T cells, as therapeutic efficacy was blunted in CD8 + T cell–depleted mice. Adaptive immune responses to combination therapy provided systemic control of contralateral tumors outside of the radiation field. Taken together, we show that a clinical candidate ATM inhibitor enhances radiation-induced T1IFN, leading to both innate and subsequent adaptive antitumoral immune responses and sensitization of otherwise resistant pancreatic cancer to immunotherapy.
- Open Access
- 10 August 2020
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-10
Prognostic value of a five-lncRNA signature in esophageal squamous cell carcinoma
Background: The aim of this study was to identify prognostic long non-coding RNAs (lncRNAs) and develop a multi-lncRNA signature for suvival prediction in esophageal squamous cell carcinoma (ESCC). Methods: The clinical and gene expression data from Gene Expression Omnibus database (GSE53624, n = 119) were obtianed as training set. A total of 98 paired ESCC tumor and normal tissues were detected by RNA sequencing and used as test set. Another 84 ESCC tissues were used for real-time quantitative PCR(qRT-PCR) and as an independent validation cohort. Survival analysis, Cox regression and Kaplan–Meier analysis were performed. Results: We screened a prognostic marker of ESCC from the GSE53624 dataset and named it as the five-lncRNA signature including AC007179.1, MORF4L2-AS1, RP11-488I20.9, RP13-30A9.2, RP4-735C1.6, which could classify patients into high- and low-risk groups with significantly different survival(median survival: 1.75 years vs. 4.01 years, log rank P < 0.05). Then test dataset and validation dataset confirmed that the five-lncRNA signature can determine the prognosis of ESCC patients. Predictive independence of the prognostic marker was proved by multivariable Cox regression analyses in the three datasets (P < 0.05). In addition, the signature was found to be better than TNM stage in terms of prognosis. Conclusion: The five-lncRNA signature could be a good prognostic biomarker for ESCC patients and has important clinical value.
- 10 August 2020
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-10
Open AccessPrognostic value of a five-lncRNA signature in esophageal squamous cell carcinoma
Background: The aim of this study was to identify prognostic long non-coding RNAs (lncRNAs) and develop a multi-lncRNA signature for suvival prediction in esophageal squamous cell carcinoma (ESCC). Methods: The clinical and gene expression data from Gene Expression Omnibus database (GSE53624, n = 119) were obtianed as training set. A total of 98 paired ESCC tumor and normal tissues were detected by RNA sequencing and used as test set. Another 84 ESCC tissues were used for real-time quantitative PCR(qRT-PCR) and as an independent validation cohort. Survival analysis, Cox regression and Kaplan–Meier analysis were performed. Results: We screened a prognostic marker of ESCC from the GSE53624 dataset and named it as the five-lncRNA signature including AC007179.1, MORF4L2-AS1, RP11-488I20.9, RP13-30A9.2, RP4-735C1.6, which could classify patients into high- and low-risk groups with significantly different survival(median survival: 1.75 years vs. 4.01 years, log rank P < 0.05). Then test dataset and validation dataset confirmed that the five-lncRNA signature can determine the prognosis of ESCC patients. Predictive independence of the prognostic marker was proved by multivariable Cox regression analyses in the three datasets (P < 0.05). In addition, the signature was found to be better than TNM stage in terms of prognosis. Conclusion: The five-lncRNA signature could be a good prognostic biomarker for ESCC patients and has important clinical value.
- 23 August 2019
- Published by Impact Journals, LLC in Aging
- Vol. 11 (16) , 6252-6272
Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas
The prediction of clinical outcome for patients with infiltrative gliomas is challenging. Although preoperative hematological markers have been proposed as predictors of survival in glioma and other cancers, systematic investigations that combine these data with other relevant clinical variables are needed to improve prognostic accuracy and patient outcomes. We investigated the prognostic value of preoperative hematological markers, alone and in combination with molecular pathology, for the survival of 592 patients with Grade II-IV diffuse gliomas. On univariate analysis, increased neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), and decreased albumin-to-globulin ratio (AGR), all predicted poor prognosis in Grade II/III gliomas. Multivariate analysis incorporating tumor status based on the presence of IDH mutations, TERT promoter mutations, and 1p/19q codeletion showed that in lower-grade gliomas, high NLR predicted poorer survival for the triple-negative, IDH mutation only, TERT mutation only, and IDH and TERT mutation groups. NLR was an independent prognostic factor in Grade IV glioma. We therefore propose a prognostic model for diffuse gliomas based on the presence of IDH and TERT promoter mutations, 1p/19q codeletion, and NLR. This model classifies lower-grade gliomas into nine subgroups that can be combined into four main risk groups based on survival projections.
- 23 August 2019
- Published by Impact Journals, LLC in Aging
- Vol. 11 (16) , 6252-6272
Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas
The prediction of clinical outcome for patients with infiltrative gliomas is challenging. Although preoperative hematological markers have been proposed as predictors of survival in glioma and other cancers, systematic investigations that combine these data with other relevant clinical variables are needed to improve prognostic accuracy and patient outcomes. We investigated the prognostic value of preoperative hematological markers, alone and in combination with molecular pathology, for the survival of 592 patients with Grade II-IV diffuse gliomas. On univariate analysis, increased neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), and decreased albumin-to-globulin ratio (AGR), all predicted poor prognosis in Grade II/III gliomas. Multivariate analysis incorporating tumor status based on the presence of IDH mutations, TERT promoter mutations, and 1p/19q codeletion showed that in lower-grade gliomas, high NLR predicted poorer survival for the triple-negative, IDH mutation only, TERT mutation only, and IDH and TERT mutation groups. NLR was an independent prognostic factor in Grade IV glioma. We therefore propose a prognostic model for diffuse gliomas based on the presence of IDH and TERT promoter mutations, 1p/19q codeletion, and NLR. This model classifies lower-grade gliomas into nine subgroups that can be combined into four main risk groups based on survival projections.